AIOSYN
Aiosyn, a medical software company that develops AI-powered pathology solutions, has been awarded a EUR 1.300.000 EFRO-OOST grant alongside Radboud university medical center and Pathologie-DNA to accelerate the development of AI technology for breast and skin cancer diagnostics. With the AIRAT project, the three organizations will join forces to introduce CE-marked deep learning algorithms for automated mitosis detection to the market.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230508005736/en/
Mitotic figures (cells that are in the process of dividing) are identified and highlighted with Aiosyn's algorithm for automated mitosis detection. (Photo: Business Wire)
Wouter Bulten, Chief innovation officer of Aiosyn: “At Aiosyn, we recognize the critical role pathologists play in diagnostics. Through close collaboration, this EFRO grant enables us to further develop AI tools that support pathologists and enhance pathology practice.”
Close to 20 million patients are diagnosed with cancer every year1. Unfortunately, incidence is expected to increase in the upcoming decades, with a predicted global burden of about 30 million new cancer cases per year by 20402. This underlines the need for new tools to improve the efficiency and accuracy of the disease diagnosis and treatment.
As part of this project, Aiosyn will further develop and validate AI-powered algorithms for breast and skin cancer diagnosis. One of such algorithms is Aiosyn’s solution for automated mitosis detection. The quantification of mitotic figures in cancer tissue is an essential part of the diagnosis of multiple tumor types. By leveraging AI-based digital biomarkers, pathologists can more accurately predict tumor growth and understand patient prognosis. This will help reduce observer variability, improve the accuracy and consistency of diagnoses, and ultimately enhance patient outcomes.
Jeroen van der Laak, professor at Radboud university medical center and CSO of Aiosyn: “Once you have decided which problem to solve, and have collected all required data, developing AI for Pathology is doable. But collecting high-quality data is tough, and getting the AI to a level that truly creates patient value is even tougher. In our AIRAT project we will tackle those challenges: collect multi-center data and move the developed AI forward to a certified product, ready to support pathologists.”
Aiosyn’s algorithms will be fully integrated in existing digital pathology workflows such as Sectra. The AI-powered solutions will aim to provide major progress in the assessment and disease management of cancer patients worldwide.
“We are excited to partner with Aiosyn and Radboud UMC on this project," said Matthijs van Oosterhout, on behalf of Pathologie-DNA, chairman of Pathologie-DNA B.V. "Together, we can leverage our respective strengths to develop AI solutions that will improve patient outcomes and advance the field of pathology. This collaboration is a great example of how start-ups and established companies can work together to drive innovation."
About Aiosyn
Aiosyn is a Dutch medical software company that develops AI-powered pathology solutions that will be integrated into standard pathology workflows. The Aiosyn team has been built upon 20+ years of research experience in the field of pathology and is rooted into the pathology practice.
About Radboud university medical center
Radboud university medical center is a university medical center for patient care, research, and education, located in Nijmegen. We mainly concentrate on prevention, meaningful and prudent healthcare, sustainability, artificial intelligence and data-driven systems, the molecular mechanisms of diseases and new treatments, and training the professionals of tomorrow.
About Pathologie-DNA
Pathologie-DNA is a collaboration between three pathology laboratories Jeroen Bosch Ziekenhuis, located in ‘s-Hertogenbosch, St. Antonius Ziekenhuis located in Nieuwegein and Rijnstate located in Arnhem. Pathologie-DNA is the partner in pathology for medical specialists, general practitioners and private diagnostic centres. We work with digital pathology. This makes it possible to provide continuous high-quality diagnostics. Consultation between colleagues and consultation with academic hospitals guarantee this quality.
Sources
1. World Cancer Day 2023: Close the care gap - PAHO/WHO | Pan American Health Organization
2. World Cancer Report: Cancer Research for Cancer Prevention (who.int)
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230508005736/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting samarbejder med TruScore14.11.2025 16:15:00 CET | Pressemeddelelse
Andersen Consulting annoncerer en samarbejdsaftale med TruScore, som styrker virksomhedens kompetencer inden for humankapital og hjælper kunder med at opbygge stærkere ledelsesteams og organisatoriske kulturer. Truscore, der har hovedsæde i USA, specialiserer sig i at levere fuldt skræddersyede survey-hosting-løsninger, der gør det muligt for organisationer at gennemføre whitelabel-vurderingsordninger, der er skalerbare, sikre og tilpasset deres specifikke behov. TruScore tilbyder avancerede 360-graders feedbackløsninger og samarbejder med Fortune 500-virksomheder, ledelsesudviklingsfirmaer og uafhængige coaches om at designe og administrere deres egne vurderingsplatforme og -oplevelser. "I nutidens dynamiske forretningsmiljø har organisationer brug for mere end blot en strategi – de har brug for stærk og robust ledelse for at kunne omsætte strategien til succes," siger Derek Murphy, CEO for TruScore. "Gennem dette samarbejde med Andersen Consulting kan vi få vores ekspertise inden for
SBC Medical Group Enters the Thai Market through Partnership with BLEZ14.11.2025 13:47:00 CET | Press release
-- Advancing Its Overseas Growth Strategy to Expand Japanese-Quality Aesthetic Medicine Across Asia Following Singapore -- SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a global provider of comprehensive consulting and management services to the medical corporations and their clinics, today announced that it has entered into a Consulting Agreement with BLEZ ASIA Co., Ltd. (Headquarters: Bangkok, Thailand; CEO: Naoki Iida; “BLEZ”), which operates more than 20 pharmacies and clinics in Thailand and is widely trusted by both Japanese expatriates and local patients. The partnership is a key component of SBC’s broader Asia strategy and represents a significant step toward full-scale entry into the rapidly growing Thai aesthetic medicine market. Under the agreement, SBC will provide comprehensive management support to a new clinic focused primarily on dermatological treatments such as pigmentation and spot removal, which BLEZ is preparing to open in
SBC Medical Group Holdings Announces Third Quarter 2025 Financial Results14.11.2025 13:00:00 CET | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a global provider of comprehensive consulting and management services to the medical corporations and their clinics, today announced its financial results for the third quarter of fiscal year 2025 (three months ended September 30, 2025) and for the third quarter cumulative of fiscal year 2025 (Year-to-Date 2025, nine months ended September 30, 2025) Third Quarter 2025 Highlights Total revenues were $43 million, representing an 18% year-over-year decrease. Income from operations was $16 million, representing a 15% year-over-year increase. Net Income attributable to SBC Medical Group was $13 million , representing an 353% year-over-year increase. Earnings per share, which is defined as net income attributable to the Company divided by the weighted average number of outstanding shares, was $0.12 for the three months ended September 30, 2025, compared to $0.03 in the same period of 2024. EBITDA1, which
Ant Group Chairman Eric Jing Outlines Strategy for Inclusive AI, Collaboration on Tokenised Settlement14.11.2025 11:15:00 CET | Press release
AI-as-a-Service applications will make AI virtual CFO and COO for SMEsPublic-private collaboration in regulatory sandboxes help to provide clarity and certainty when it comes to new technology like tokenisation and AI Eric Jing, Chairman of Ant Group, said the company's focus is on putting new payment and operation tools powered by AI and tokenisation technology in the hands of SMEs, to fully embrace the next wave of global productivity revolution. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251114239737/en/ Ant Group Chairman Eric Jing (second from right) shares insights during a panel discussion titled “Steering the Global Future” during the Singapore FinTech Festival on November 14, 2025. “We are passionate about using frontier technology to support SMEs and the use of AI will really uplift inclusion,” Jing said during a panel discussion titled “Steering the Global Future” during the Singapore FinTech Festival on Novem
Allianz Achieves Record Results and Expects a Full-Year Operating Profit of at Least 17 Billion Euros14.11.2025 07:16:00 CET | Press release
3Q 2025 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251113803211/en/ Oliver Bäte, Chief Executive Officer of Allianz SE Double-digit growth in operating profit and shareholders’ core net incomeTotal business volume rises 5.21 percent with contributions from all segments Operating profit increases 12.6 percent to 4.4 billion euros, with particular strong contribution from the Property-Casualty segment Shareholders’ core net income advances by 12.7 percent and reaches 2.9 billion euros 9M 2025 Continued strong and diversified growth across our businessesand record operating profitTotal business volume rises 8.5 1 percent and reaches 141.2 billion euros with contributions from all segments Operating profit increases 10.4 percent to 13.1 billion euros, our highest nine-month operating profit ever, reaching 82 percent of our full-year outlook midpoint Shareholders’ core net income advances 10.5 percent to 8.4 billion euros. Ad
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom